Much progress has been made in diabetes technology over the past decade. Continuous glucose monitoring has achieved high accuracy and reliability, resulting ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

Germantown, Maryland Monday, February 10, 2025, 16:00 Hrs [IST] ...

Wearables have become catalysts for a proactive approach to healthcare, predicting what is about to happen based on current ...

Completing the CE Mark submission for Eversense 365 brings us a step closer to improving lives and health outcomes for ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Smart watches, rings, and a growing array of patches are adding more functionality and being used across a growing set of applications.